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Abstract: Various drugs and surgical procedures have been utilized for the treatment of 
trigeminal neuralgia (TN). Despite numerous available approaches, the results are not com-
pletely satisfying. The need for more contemporaneous drugs to control the pain attacks is a 
common experience. Moreover, a number of patients become drug resistant, needing a surgical 
procedure to treat the neuralgia. Nonetheless, pain recurrence after one or more surgical opera-
tions is also frequently seen. These facts reflect the lack of the precise understanding of the TN 
pathogenesis. Classically, it has been related to a neurovascular compression at the trigeminal 
nerve root entry-zone in the prepontine cistern. However, it has been evidenced that in the pain 
onset and recurrence, various neurophysiological mechanisms other than the neurovascular 
conflict are involved. Recently, the introduction of new magnetic resonance techniques, such as 
voxel-based morphometry, diffusion tensor imaging, three-dimensional time-of-flight magnetic 
resonance angiography, and fluid attenuated inversion recovery sequences, has provided new 
insight about the TN pathogenesis. Some of these new sequences have also been used to better 
preoperatively evidence the neurovascular conflict in the surgical planning of microvascular 
decompression. Moreover, the endoscopy (during microvascular decompression) and the 
intraoperative computed tomography with integrated neuronavigation (during percutaneous 
procedures) have been recently introduced in the challenging cases. In the last few years, 
efforts have been made in order to better define the optimal target when performing the gamma 
knife radiosurgery. Moreover, some authors have also evidenced that neurostimulation might 
represent an opportunity in TN refractory to other surgical treatments. The aim of this work 
was to review the recent literature about the pathogenesis, diagnosis, and medical and surgical 
treatments, and discuss the significant advances in all these fields.
Keywords: microvascular decompression, percutaneous balloon compression, gamma knife 
radiosurgery, surgical treatment, magnetic resonance imaging, therapy
Introduction
Trigeminal neuralgia (TN) is a facial pain syndrome characterized by paroxysmal, 
shock-like pain attacks located in the somatosensory distribution of the trigeminal 
nerve. The prevalence of TN in the general population is 0.015%.1 Facial pain 
has a considerable impact on quality of life. It has been recently shown that TN is 
the most frequent type of facial pain2 and that, among facial pain syndromes, the 
overall incidence of TN has remained constant3 ranging from 12.6/100,000/year2 to 
27/100,000/year.3 TN is uncommon in population younger than 40 years (overall inci-
dence of 0.2/100,000/year) and increases in incidence with advancing age, occurring 
in 25.9/100,000/year in individuals older than 80 years.4 TN appears to be slightly 
more common among women and has both classical and symptomatic (~15% of 
cases) subtypes with the former most often associated with a neurovascular conflict 
of the trigeminal nerve in the prepontine cistern.5 The right side is more frequently 
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involved.6 When TN occurs in young age or presents with 
bilateral symptoms, lack of triggered pain, absence of a 
refractory period, or an abnormal neurologic examination, 
secondary causes such as multiple sclerosis (MS) should 
be suspected.5 Bilaterality may be seen in 5% of classical 
cases, but even in these cases, synchronous pain is not 
observed. Patients with bilateral TN often have a positive 
family history.7 In patients affected by MS, prevalence is 
higher, ranging from 1%8 to 6.3%.9 In these patients, in 
addition to the episodic pain, a constant pain component 
is often complained. Although in these patients, pain is 
mainly unilateral, bilateral involvement can occur up to 
31% of patients.10
Advances in diagnosis
Clinical criteria for TN
The International Headache Society recently defined strict 
clinical criteria for TN diagnosis.11 According to these 
criteria, a diagnosis of TN can be made when at least three 
attacks of unilateral facial pain occur fulfilling these criteria: 
1) occurring in one or more divisions of the trigeminal nerve, 
with no radiation beyond the trigeminal distribution and 
2) pain with at least three of the following four characteristics: 
a) recurring in paroxysmal attacks lasting from a fraction 
of a second to 2 minutes; b) severe intensity; c) electric 
shock-like, shooting, stabbing, or sharp in quality; and 
d) precipitated by innocuous stimuli to the affected side of 
the face. Important criteria for clinical diagnosis are also the 
lack of evident neurologic deficit and a pain that cannot be 
attributed to another disorder. Moreover, to rationalize the 
different subtypes of facial pain, a new classification scheme 
that divides facial pain into several distinct categories has 
been recently introduced.12
More specifically, in this new classification,12 it has been 
proposed to differentiate TN into: 1) type 1 (previously 
referred to as classic or typical TN), which is an idiopathic 
episodic pain with the previously reported clinical charac-
teristics, lasting several seconds, with pain-free intervals 
between attacks and 2) type 2, describing idiopathic trigemi-
nal facial pain that is aching, throbbing, or burning for more 
than 50% of the time and is constant in nature (constant 
background pain being the most significant attribute) with 
a minor component of sharp, episodic pain. It has also been 
theorized that TN type 1 can progress toward TN type 2 and 
that in this second type, the likelihood of detecting a structural 
abnormality such as a tumor or a vascular malformation is 
higher.12
Nonetheless, the neurophysiological recording of 
trigeminal reflexes represents a useful and reliable test for 
the TN diagnosis, according to the European Federation of 
Neurological Societies (EFNS) guidelines on neuropathic 
pain assessment13 and the American Academy of Neurol-
ogy–EFNS guidelines on TN management (Table 1).14,15 
In cases of symptomatic TN, neurophysiological testing 
of trigeminal reflexes seems to provide the same sensitiv-
ity (95%) and specificity (93%) as magnetic resonance 
imaging (MRI).16 Advances in MRI have been playing an 
important role in the diagnostic setting, especially in the 
Table 1 AAN–eFNS guidelines on TN management
Topic Recommendations
Diagnosis For patients with TN without non-trigeminal neurological symptoms, routine imaging  
may be considered to identify STN (Level C)
Younger age of onset, involvement of the first division of the trigeminal nerve,  
unresponsiveness to treatment, and abnormal trigeminal-evoked potentials should  
be disregarded as useful for disclosing STN (Level B)
Determining the presence of trigeminal sensory deficits or bilateral involvement  
of the trigeminal nerves should be considered useful to distinguish STN from CTN  
However, the absence of these features should be disregarded as useful for distinguishing  
STN from CTN (Level B)
Measuring trigeminal reflexes in a qualified electrophysiological laboratory should  
be considered useful for distinguishing STN form CTN (Level B)
Pharmacological treatment CBZ is established as effective (Level A) and OXC is probably effective (Level B) for controlling pain in CTN
Baclofen, lamotrigine, and pimozide may be considered to control pain in patients with CTN (Level C)
Topical ophthalmic anesthesia is probably ineffective in controlling pain in patients with CTN (Level B)
Surgical treatment For patients with TN refractory to medical therapy, early surgical therapy may be considered (Level C)
Percutaneous procedures on the Gasserian ganglion, gamma knife, and MvD may be considered (Level C)
MVD may be considered over other surgical techniques to provide the longest duration of pain freedom (Level C)
Abbreviations: AAN, American Academy of Neurology; eFNS, european Federation of Neurological Societies; TN, trigeminal neuralgia; STN, symptomatic trigeminal 
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Diagnosis and treatment of trigeminal neuralgia
presurgical evaluation of TN patient in order to identify 
secondary causes of TN and/or the neurovascular conflict. 
Studies have been published17,18 on the usefulness of three-
dimensional fast imaging employing steady-state acquisition 
and magnetic resonance angiography (MRA) in surgical 
planning and prediction of surgical findings during micro-
vascular decompression (MVD). A correlation more than 
95% between this method and surgical findings has been 
demonstrated.17,18
Pathophysiological theories
Classically, TN has been related to a neurovascular compres-
sion in the prepontine cistern at the nerve root entry-zone due 
to an abnormal artery or vein, arteriovenous malformation, 
vestibular schwannoma, meningioma, epidermoid cyst, 
tuberculoma, various other cysts and tumors, aneurysm, ves-
sels aggregation, and arachnoiditis.19–21 MS, diabetes mellitus, 
odontogenic inflammatory diseases, and otolaryngological 
pathology, such as sinusitis, have also been proposed as 
causes of TN.22–31
From a pathogenic point of view, TN shows a high 
complexity related to the involvement of various underlying 
neurophysiological mechanisms. Activation of peripheral 
receptor, transmission and projection of nociceptive informa-
tion, and convergence of nociceptive afferents onto common 
central neurons,32 as well as the interaction of a multitude of 
neurotransmitters and neuromodulators, may play a key role 
in the perception of pain.33
Trigeminal convergence-projection theory
In the trigeminal convergence-projection theory, it has 
been hypothesized that continuous or recurrent noci-
ceptive inputs from head and neck converge on spinal 
trigeminal nucleus (subnucleus caudalis), where the 
release of neurotransmitters and vasoactive substances 
may be promoted.34,35 This release decreases the threshold 
of adjacent second-order neurons that receive input from 
sites other than nociceptive sources. The signals from these 
excited second-order neurons may be transmitted to the 
thalamus, limbic system, and somatosensory cortex and 
interpreted as pain.36
Bioresonance hypothesis
Recently, the bioresonance hypothesis for TN pathogenesis 
has been proposed. This theory states that when the vibration 
frequency of a structure surrounding the trigeminal nerve 
becomes close to its natural frequency, the resonance of 
the trigeminal nerve occurs. The bioresonance can damage 
trigeminal nerve fibers and lead to the abnormal transmission 
of the impulse, which may finally result in facial pain.37
ignition hypothesis
According to the ignition hypothesis, based on recent 
advances in the understanding of the electrical behavior of 
injured sensory neurons and on findings from histopatho-
logic observations obtained from patients undergoing MVD, 
injury of trigeminal afferent neurons in the trigeminal root 
or ganglion makes these axons and axotomized somata 
hyperexcitable, giving rise to pain paroxysms as a result of 
synchronized afterdischarge activity.38
Pathogenesis possibilities from brain 
imaging studies
New insights about the pathogenesis of TN have been coming 
from new MRI studies, such as voxel-based morphometry,39 
diffusion tensor imaging (DTI),40 three-dimensional time- 
of-flight (TOF) MRA, and fluid-attenuated inversion recov-
ery DTI-sequences.41 Moreover, it has been evidenced that 
using functional MRI (fMRI), changes in brain activity 
associated with stimulation of the cutaneous trigger zone in 
patients with TN can be analyzed. Recently, Moisset et al42 
showed that painful stimuli in TN patients were associated 
with significantly increased activity in the spinal trigeminal 
nucleus, thalamus, primary and secondary somatosensory 
cortices, anterior cingulate cortex, insula, premotor/motor 
cortex, prefrontal areas, putamen, hippocampus, and brain-
stem and that non-painful stimulation of the trigger zone 
activated all but three of these structures (spinal trigeminal 
nucleus, brainstem, and anterior cingulate cortex). This 
wide involvement of different neural structures also during 
non-painful stimulation of the trigger zone suggests a state 
of maintained sensitization of the trigeminal nociceptive 
systems. Interestingly, after a successful surgical treatment, 
the activation of the operated side was confined only to 
primary and secondary somatosensory cortices.42 A gray 
matter volume reduction in TN patients was found, using 
voxel-based morphometry, in the primary somatosensory 
and orbitofrontal cortices, as well as in the secondary 
somatosensory cortex, thalamus, insula, cerebellum, and 
dorsolateral prefrontal cortex. Gray matter volume decreased 
within the anterior cingulate cortex, parahippocampus, and 
temporal lobe and correlated with increasing disease dura-
tion in TN, reflecting adaptation mechanism to chronic pain 
with regard to neuronal plasticity.39 Similarly, using DTI, a 
lower fractional anisotropy, reflecting an abnormal tissue 
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and in white matter in the brain, suggesting that trigeminal 
nerve structural abnormalities occur in TN, even if not appar-
ent on gross imaging.40 To investigate microstructural tissue 
changes of trigeminal nerve in patients with unilateral TN, 
Liu et al41 used TOF MRA and fluid-attenuated inversion 
recovery DTI-sequences, and measured fractional anisotropy, 
mean diffusivity, axial diffusivity, and radial diffusivity on 
the involved trigeminal nerve. They found that the affected 
side showed significantly decreased fractional anisotropy 
and increased radial diffusivity, suggesting that demyelina-
tion without significant axonal injury is an important factor 
in TN pathogenesis.41 Moreover, these new MRI techniques 
together with trigeminal tractography have also been utilized 
to identify microstructural changes in the trigeminal nerve 
after radiosurgery and possibly monitor the response to this 
treatment. In patients submitted to radiosurgery, a drop in 
fractional anisotropy values at the target with no significant 
change outside the target was evidenced, demonstrating 
highly focal changes after treatment. Radial diffusivity also 
changed markedly, suggesting that radiosurgery primarily 
affects myelin. Fractional anisotropy changes were detected 
regardless of trigeminal nerve enhancement, suggesting more 
sensitivity of tractography than conventional gadolinium-
enhanced post-treatment MRI. In subjects with long-term 
follow-up, recovery of fractional anisotropy/radial diffusivity 
correlated with pain recurrence.43
Advances in medical therapy
Historical and current medical therapy
Phenytoin was the first drug used for TN with reported 
positive effects.44 However, according to the recent EFNS 
guidelines,13 two drugs are considered as first-line therapy in 
TN: carbamazepine (CBZ; 200–1,200 mg/day) and oxcarba-
zepine (OXC; 600–1,800 mg/day). The effectiveness of CBZ 
was demonstrated in several studies.45–50 Specifically, CBZ 
has been found to reduce both the frequency and intensity 
of painful paroxysms and was equally efficacious on spon-
taneous and trigger-evoked attacks.45 Nevertheless, frequent 
adverse event has been reported during CBZ therapy, espe-
cially in elderly patients.51–53 Thus, OXC is often used as 
initial treatment for TN54 due to accepted greater tolerability 
and decreased potential drug interactions.55 Three random-
ized controlled trials, comparing OXC (600–1,800 mg/day) 
to CBZ in TN patients,56,57 reported a reduction in the num-
ber of attacks and pain assessments equally good for both 
CBZ and OXC with more than 80% of patients responding 
to these drugs. Other drugs have been used in TN: baclofen 
was found to be superior to placebo in reducing the number 
of pain attacks.58 Lamotrigine,59 pimozide,60 and tocainide61 
were reported to have good efficacy on pain attacks control. 
Lamotrigine in combination with CBZ or phenytoin was also 
found to be more effective than placebo.59,62 In patients having 
already undergone trigeminal surgery or taking concurrent 
medications, tizanidine was found to be better than placebo, 
but its effect decayed within 1–3 months.63
emerging medical therapy
It is common experience that TN can be difficult to treat 
and can recur after surgical treatments in patients under 
therapy with more drugs used in combination. Thus, new 
therapeutic modalities have been tried. More specifically, 
according to a recent overview,64 gabapentin combined with 
regular ropivacaine injections into trigger sites improved 
pain control and quality of life, and pregabalin was found 
to be effective at 1 year follow-up in TN patients. Recently, 
Hu et al65 systematically reviewed the therapeutic efficacy 
and safety of injection of botulinum toxin type A (BTX-A) 
in TN and found a response in approximately 70%–100% 
of patients with mean pain intensity and frequency reduced 
by approximately 60%–80% with no major adverse events 
reported. On these bases, they concluded that BTX-A may be 
effective in treatment of TN. These results are in agreement 
with Cruccu and Truini,66 who recently reviewed the literature 
on the medical management of refractory TN and found that 
there is increasing evidence that BTX-A injections are effi-
cacious and may be offered to patients before surgery or to 
patients unwilling to undergo surgery. Although it represents 
a promising treatment of TN with favorable risk-to-benefit 
ratio, to investigate the optimal dose of BTX-A treatment, the 
duration of therapeutic efficacy, the side effects, and the time 
and indications for repeat injection, further well-designed, 
randomized, controlled, double-blinded trials are needed. 
As recently evidenced, a problem in TN is the treatment of 
the acute crisis, where local anesthesia, such as ropivacaine, 
injected into a trigger area, an 8% spray of lidocaine, and the 
intravenous infusion of fosphenytoin can provide temporary 
pain relief.64
Advances in surgical therapy
Various surgical approaches have been proposed for the 
treatment of drug-resistant TN. MVD is performed with 
the objective to resolve the neurovascular conflict between 
an abnormal vessel and the trigeminal nerve. On the other 
hand, percutaneous destructive procedures, involving a trans 
foramen ovale approach to the retrogasserian portion of the 
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Diagnosis and treatment of trigeminal neuralgia
aiming at damaging the trigeminal nerve root with a high 
and concentrated dose of radiation, have been developed 
during the past years. While there is a wide literature about 
the surgical treatment of TN,67,68 the difficulty to evaluate 
the quality of published surgical reports is an emerging 
problem69 as recently evidenced by international guidelines 
and systematic reviews.67,70
MvD
MVD is based on the assumption that a compression of 
trigeminal nerve by an abnormal vascular loop is the direct 
cause of TN.71 Obviously, preoperatory radiological studies 
are mandatory in order to identify the abnormal vessels and 
the conflict with the nerve. Recently, three-dimensional 
fast imaging employing steady-state acquisition sequence 
that produces a very high-resolution T2-weighted MRI 
with an excellent contrast between structures, including 
cerebrospinal fluid, trigeminal nerve and adjacent blood 
vessels, and TOF MRA have been introduced. MVD has 
become one of the most common treatments for TN provid-
ing long pain relief. Unfortunately, not all patients achieve 
a good outcome after MVD.14 The reported pain-free dura-
tion without medication after MVD ranges from 0.6 years 
to 10 years.72 After 5 years, the percentage of patients free 
of pain ranges from 58% to 78%.73,74 It has been reported 
that patients with typical TN and immediate postoperative 
remission have more often an excellent/good postoperative 
outcome, being the immediate postoperative remission an 
independent predictive factor for good long-term outcome.74 
Unfortunately, as recently evidenced, no randomized con-
trolled trials of reasonable quality have investigated the 
role of MVD in the TN treatment.64,70 Moreover, little is 
reported in the literature about the quality of life after MVD, 
but it has been evidenced as patients undergoing primary 
surgery with no recurrence and no complications show no 
evidence of depression and are very satisfied after MVD.75 
Described complications after this procedure are infections 
(Figure 1), facial palsy, facial numbness, cerebrospinal fluid 
leak, and hearing deficit with a mortality of 0.1%.76 Obvi-
ously, complications and side effects reduce satisfaction 
mainly after the partial sensory rhizotomy, which causing 
a sensory loss can lead to keratitis and eating difficulties, 
decreasing satisfaction of these patients compared to MVD 
patients.75 It is a common experience that in some cases, 
identifying the neurovascular conflict cannot be easy during 
surgery. Recently, some authors reported the use of endo-
scope as a significant aid in patients with a bony ridge obscur-
ing the view of the fifth nerve, with a very distal vascular 
compression, or if a combination of both occurs.76,77 Broggi 
et al76 reported 8.5% of cases in whom conflict was not clearly 
visible with the microscope but revealed and solved with the 
endoscope. A fully endoscopic MVD has been described78 
with pain outcome and rate of complications very similar to 
microscopic MVD.77,79
Figure 1 Postoperative CT scan of a 40-year-old man submitted to MvD for right TN (A; red arrow). Brain axial MRi after gadolinium administration (B) 2 months after 
MvD, showing an abscess at the site of operation (yellow arrow).
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Percutaneous balloon compression (PBC) was introduced in 
the clinical setting by Mullan et al79,80 and has been exten-
sively used in the treatment of TN due to low cost, simplicity, 
and the advantage of being the only percutaneous procedure 
performed with the patient under general anesthesia. There 
is a general consensus about the usefulness of PBC either 
in general population67 or in MS patients.26,68 PBC offers a 
good rate of immediate postoperative pain relief ranging 
from 80% to 90%67,81,82 and a pain-free time without medi-
cation that ranges from 2 years to 3 years.82,83 However, no 
reports about the long-term quality of life of these patients 
are available in the literature. Some authors suggested84,85 
a lower efficacy in patients previously treated with other 
surgical procedures, in cases with positive history of MS 
and when a pear-like shape of the balloon at the operation 
is not obtained.86 Complications can include numbness, dys-
esthesia, and, more rarely, masseter weakness that usually 
resolves within some months; meningitis and cranial nerve 
deficits are less common.82,87,88 There are no standardized 
criteria concerning the compression time and the compression 
pressure. While experimental animal models suggest that a 
long compression time is associated with better outcome,89 
these data are not confirmed in the clinical setting where 
there are consistent data that a longer compression time does 
not affect the pain relief and only increase the complication 
rate.86,90,91 Moreover, higher balloon pressures have been 
associated with higher rates of dysesthesia,severe numbness, 
and masseter weakness.92 The variability of Meckel’s cave 
size has been advocated as another factor involved in the effi-
cacy of the procedure; thus, cannulas of different sizes have 
been designed.93 Technical failure to cannulate the foramen 
ovale using fluoroscopy can be a significant problem in some 
cases, but recently, intraoperative computed tomography with 
integrated neuronavigation has been safely used in reoperated 
patients due to prior failure under fluoroscopy.94
Glycerol rhizotomy
The injection of glycerol in the trigeminal cistern determines 
pain relief in patients with TN due to demyelination and 
axonal fragmentation.95,96 Since its introduction,97,98 this 
technique has remained relatively unchanged with a reported 
initial pain relief more than 90%99 and a rate of pain-free 
patients at 3 years of almost 50%.100,101 There are evidences 
that the success of glycerol rhizotomy depends on some 
degree of sensory loss postoperatively96,102,103 and that the 
chance of good outcome would be increased if facial pain 
was present during glycerol injection.96 Dysesthesias, corneal 
numbness, masseter weakness, and herpes labialis have been 
reported as frequent complications of this procedure.87,96,101 
Recently, Goodwin et al104 performed a MVD with injec-
tion of glycerol to the inferior third cisternal portion of the 
nerve, anterior to the root entry-zone, in 14 patients without 
neurovascular conflict on pre-operative MRI, reporting an 
80% of good response at 3 months follow-up.
Radiofrequency thermocoagulation
Radiofrequency thermocoagulation is based on the attempt 
to electrocoagulate the trigeminal nerve and Gasserian 
ganglion rootlets.105,106 An initial pain relief more than 90% 
with a recurrence rate of up to 25% has been reported.107,108 
The reported side effects, such as masticatory weakness, 
dysesthesia, and corneal numbness, seem to be related to 
significant individual variation of somatotopic organization 
of trigeminal nerve fibers and the irreversible damage of 
small, unmyelinated pain fibers.109,110 To overcome these 
limitations, a quadripolar electrode improving the accuracy 
of somatotopic identification, decreasing the lesion size, 
and reducing the unwanted injury has been developed.111 
A decrease in the incidence of masseter weakness and unde-
sirable paresthesias and an improvement in the immediate 
pain relief rate using a curved tip electrode has previously 
been reported.112 Moreover, the use of neuronavigator and 
computer tomography to improve needle localization seems 
to be associated with lower complications and recurrence 
rate compared to standard fluoroscopy in recent studies.113,114 
Pulsed radiofrequency had been introduced with the aim to 
reduce the incidence of side effects; however, as recently 
reported in a prospective, randomized, double-blinded study 
comparing the effect of pulsed radiofrequency and conven-
tional radiofrequency, although none of the patients in the 
pulsed radiofrequency group showed paresthesia, pain relief 
was not satisfactory as it was expected.115
Gamma knife radiosurgery
GKRS has been used as a treatment modality in several 
centers for patients with concurrent medical illness who 
were poor candidates for MVD or who refuse more invasive 
surgery.116,117 Usually, the root entry-zone of the trigemi-
nal nerve is used as a target and the dose protocols range 
from 70 Gy to 100 Gy.118–121 Nonetheless, considering that 
the underlying mechanisms are not fully understood, to date 
there is still uncertainty about the exact target and optimum 
dose to be used. In many clinical target volume definitions, 
the root entry-zone of the trigeminal nerve situated at 2–3 mm 
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Diagnosis and treatment of trigeminal neuralgia
the radiosurgical target appeared to affect the duration of 
pain relief with the target closer to the brainstem, providing 
extended pain relief. However, the proximal radiosurgical 
target was also associated with an increased risk of mild to 
moderate facial numbness.123 Alternative targets include 
the trigeminal nuclei in the brainstem or the centromedian 
nucleus of the thalamus.124 In general, it has been reported 
that higher doses of radiation are related to better outcomes, 
but complications increase at doses greater than 90 Gy.120,125 
In published long-term follow-up studies, the mean maximal 
radiation dose was approximately 80 Gy, and complications 
included facial numbness, which affected approximately 10% 
of the treated patients.126–128 Moreover, permanent dysesthe-
sias and anesthesia dolorosa affecting the quality of life have 
been reported.129 Although GKRS achieves relatively good 
outcomes on initial pain relief, the results suggest a rate of late 
failure, particularly among patients who performed GKRS 
following prior surgery.130 Little et al126 reported that 75% of 
patients with no previous surgery achieved long-term pain 
relief at 7 years compared with only 10% of patients with 
previous surgery. GKRS requires a delay before pain relief 
occurs. For this reason, some authors suggest that patients 
with extreme pain in need of fast relief should undergo other 
procedures.131 Recently, it has been evidenced that overall 
pain relief following GKRS was comparable in patients 
with and without evidence of vascular compression on MRI. 
In the subgroup analysis of those with MRI evidence of 
vessel impingement of the affected trigeminal nerve, pain 
relief correlated with a higher dose to the point of contact 
between the impinging vessel and the trigeminal nerve.132 
Nonetheless, in a recent prospective cohort study comparing 
GKRS and MVD, the last one was significantly superior to 
GKRS in maintaining a pain-free status and provided simi-
lar early and superior longer-term patient satisfaction rates 
compared to GKRS.133
Neuromodulation, really a chance for TN?
Two kinds of neuromodulation have been reported as optional 
treatments for chronic pain, refractory to conventional medi-
cal and surgical treatment: motor cortex stimulation (MCS) 
and deep brain stimulation (DBS). Chronic stimulation 
of the precentral cortex for the treatment of pain was first 
reported by Tsubokawa et al134 in 1991, and several studies 
have documented excellent results of using MCS for the 
treatment of trigeminal neuropathic pain, with 75%–100% 
of patients achieving good to excellent pain relief.135–139 
Nevertheless, these studies, mostly focusing on the use of 
MCS in pain syndrome, report few patients with idiopathic 
TN,137–139 with a limited follow-up.139 On the other hand, DBS 
has been applied in the treatment of medically and surgically 
refractory chronic pain since 1997.135,140–143 According to an 
interesting hypothesis, one of its main target, the posterior 
hypothalamus (pHyp), controls relationship between the 
neuropsychological circuits involved in pain behavior and 
the neurovegetative system. Franzini et al144 reported the first 
series of chronic pHyp stimulation, and since then, many 
authors have proposed it to treat severe pain syndromes. In 
a systematic review,145 the same authors reported that none 
of the four patients suffering from refractory neuropathic 
trigeminal pain benefited from the procedure, whereas all five 
patients affected with refractory TN due to MS and under-
going pHyp DBS experienced a significant decrease in pain 
attacks within the first trigeminal branch. Nevertheless, better 
results were obtained in chronic cluster headache and short, 
unilateral neuralgiform headache attacks with conjunctival 
injection and tearing. As for MCS, the limited number of 
studies and the relatively short follow-up make difficult to 
fully evaluate the efficacy of neuromodulation procedures. 
However, neurostimulation might represent an opportunity 
in TN refractory to other surgical treatments.
Conclusion
The treatment of TN is a challenge both for neurologists 
and neurosurgeons. The lack of a full comprehension of the 
complex pathogenesis at the basis of TN remains a key fac-
tor explaining the results that are not always satisfying with 
the medical therapy. Progress has been made in the recent 
years both for the pathogenesis and surgical treatment due to 
implementation of neuroradiological techniques. Surgery has 
also taken advantage from the introduction of the endoscope 
and neuronavigation in the operating room. New drugs, such 
as BTX-A, may be offered to patients before surgery or to 
patients unwilling to undergo surgery. Better definition of 
GKRS targets would improve the results of this technique. 
Neurostimulation might represent an opportunity in patients 
refractory to other surgical treatments, but further studies are 
needed due to the few cases treated.
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